Effect of budesonide inhalation joint montelukast in the treatment of children with mycoplasma pneumonia cough / 中国基层医药

ABSTRACT

Objective To observe the effect of budesonide inhalation joint montelukast in the treatment of children with mycoplasma pneumonia cough.Methods 176 children with mycoplasma pneumonia cough were chosen.According to the order of admission,they were divided into observation group and control group.Control group was given montelukast sodium chewable tablets treatment,the observation group was given budesonide inhalation on the basis of treatment of control group.After treatment,the efficacy,prognosis and compliance were observed.Results Before treatment,the cough scores between the two groups had no significant difference (P>0.05).After treatment, the degree of cough in the two groups were significantly improved, the cough score of the observation group from (7.4 ±2.2)points decreased to (1.5 ±0.6)points (t=24.271,P0.05).The relapse rate of the observation group was 7.95%,which was significantly lower than 18.18%of the control group, the difference between the two groups was statistically significant ( P <0.05 ) .Conclusion Budesonide inhalation joint montelukast in the treatment of mycoplasma pneumonia cough has significant effect,it has less adverse effects,good safety,and children without any discomfort,so it worthy of clinical application.